The Estée Lauder Companies announced a minority investment in 111Skin, a luxury clinical skin care brand founded by plastic and reconstructive surgeon Dr. Yannis Alexandrides. 

Founded in 2012, 111Skin was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is NAC Y2, a pioneering complex designed to support skin repair and maintain a healthy, radiant, and resilient complexion. 

Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies, said, 

“Skin care is entering a new phase, shaped by the convergence of procedures, longevity, and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results. 111Skin exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments and built on clinical insight, next-generation actives, powerful formulas, and proven efficacy.”

Building on the foundation of this clinical expertise, 111Skin has developed a portfolio of over 30 products, anchored by its Black Diamond and Reparative collections.

111Skin products are distributed through luxury retail, e-commerce, and high-end spa channels, including Harrods, Bluemercury, Nordstrom, Mandarin Oriental, Aman, and DTC.

The brand also has a diversified global footprint, with North America representing approximately 40% of 2025 sales, and an established presence across China, the United Kingdom, Europe, and the Asia Pacific.

La Faverie added,

“This investment, grounded in consumer-centricity and transformative innovation, reflects our Beauty Reimagined vision and underscores the significant opportunity we see to support the brand’s continued growth – expanding its global reach while preserving the distinctive approach that has made it so relevant with today’s consumers.”

Dr. Alexandrides will remain actively involved in the brand and will continue to lead 111Skin alongside its experienced management team.

This investment aligns with The Estée Lauder Companies’ continued focus on science-driven innovation, as 111Skin’s advanced NAC Y2 technology and commitment to clinical-led product development reflect consumers’ growing preference for high-performance and preventative skin care.

Terms of the agreement were not disclosed.

Read Next

Estee Lauder Companies Estimates $1.14 Billion in Restructuring

ELC Seeks Funding for Puig Deal, According to Reports

ELC Unpacks Dr. Jart From Group Sale, According to Reports